1. Home
  2. PCRX

as 10-07-2025 3:29pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Founded: 2006 Country:
United States
United States
Employees: N/A City: BRISBANE
Market Cap: 1.2B IPO Year: 2011
Target Price: $32.40 AVG Volume (30 days): 532.5K
Analyst Decision: Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.81 EPS Growth: N/A
52 Week Low/High: $15.16 - $27.64 Next Earning Date: 11-05-2025
Revenue: $705,848,000 Revenue Growth: 2.25%
Revenue Growth (this year): 7.36% Revenue Growth (next year): 10.07%

Stock Insider Trading Activity of Pacira BioSciences Inc. (PCRX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Ceesay Abraham PCRX Director Sep 4 '25 Sell $27.19 2,354 $64,005.26 9,039
BIGAL MARCELO PCRX N/A Aug 7 '25 Sell $23.67 4,912 $116,267.04 11,393

Share on Social Networks: